FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

FDA Clears Depuy Synthes Spinal Screw Systems

FDA clears a DePuy Synthes 510(k) for the Viper and Expedium Fenestrated Screw Systems.

Human Drugs

GDUFA 2 Changes Benefit Small Businesses: SBIA

CDERs Gisa Perez says the GDUFA agreement pending before Congress contains three financial provisions intended to address concerns of small businesses...

Federal Register

FDA Clears GEO Bone Screw System

FDA clears a Gramercy Extremity Orthopedics (GEO) 510(k) for the GEO Bone Screw System, which can be used for bone fractures, osteotomies, arthrodesis...

Human Drugs

Comparative Safety of HER2 Antagonists Outlined

An Advera Health evidence review says that Genentechs Kadcyla and Perjeta have multiple unlabeled adverse events that appear on its Herceptin label.

Medical Devices

Medical Device Prospective Active Surveillance Works: Study

An FDA-funded study demonstrates the ability of prospective, active surveillance of a representative clinical registry to identify potential safety si...

Human Drugs

Product Quality Microbiology Info MAPP

The CDER Office of Pharmaceutical Quality issues a MAPP to help product quality microbiology reviewers locate needed information in applications filed...

Human Drugs

Orphan Drug Requests Way Up, Approvals Down Slightly: Attorney

Attorney Kurt Karst says the overworked FDA Office of Orphan Product Development received 582 requests for orphan drug designations in 2016 and approv...

Human Drugs

Hospira Recalls Vancomycin Lot Due to Particulate Matter

Hospira recalls one lot of vancomycin hydrochloride for injection due to a confirmed customer report of particulate matter within a single vial.

Biologics

CBER Posts Eligibility Criteria for Regenerative Advanced Therapies

CBER posts eligibility criteria for qualifying a product as a regenerative advanced therapy and an accelerated approval pathway as mandated by the 21s...

Biologics

FDA Priority Review for Genentech Actemra sBLA

FDA accepts for priority review a Genentech supplemental BLA for Actemra (tocilizumab) for treating giant cell arteritis, a chronic, potentially life-...